Endocrine Abstracts

Background: Peptide receptor radionuclide therapy (PRRT) is a promising radiation-based therapy for metastatic neuroendocrine tumors (NETs) but remains palliative. Peptidyl-prolyl cis-trans isomerase (Pin1) is an evolutionally conserved enzyme that catalyzes the cis-trans isomerization of phosphorylated serine/threonine-proline motifs of its substrates and has recently been involved in DNA double strand break (DSB) repair in BRCA-proficient breast cancer cells. Here we study w...

Background: The use of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs) is increasing, but PRRT remains palliative at this time. Estrogen (E2) has been extensively linked to cellular proliferation and DNA repair in other cancers. Our aim is to determine whether NET cells are similarly affected by estrogen and whether inhibition of estrogen receptor alpha (ESR1) increases radiosensitivity of NET cells, which could improve PRRT response.<p class=...

Background: Neuroendocrine tumors (NETs) represent a heterogenous group of neoplasms and their diagnosis can be challenging. In 2019, FDA approved 68Gallium labeled DOTATATE PET tracer for SSTR2 overexpressing NETs, which has been widely adopted since. However, limitations of 68Ga-DOTATATE have led to the development of additional radiotracers for the diagnosis of NETs. Herein we report on a novel PET tracer using 43Sc for DOTATATE labeling. <s...